PMID- 35001080
OWN - NLM
STAT- MEDLINE
DCOM- 20220712
LR  - 20221106
IS  - 1476-5640 (Electronic)
IS  - 0954-3007 (Linking)
VI  - 76
IP  - 7
DP  - 2022 Jul
TI  - Using the optimal method-explained variance weighted genetic risk score to 
      predict the efficacy of folic acid therapy to hyperhomocysteinemia.
PG  - 943-949
LID - 10.1038/s41430-021-01055-5 [doi]
AB  - BACKGROUND: Genetic risk score (GRS) is a useful way to explore genetic 
      architectures and the relationships of complex diseases. Several studies had 
      revealed many single nucleotide polymorphisms (SNPs) associated with the efficacy 
      of folic acid treatment to hyperhomocysteinemia (HHcy). METHODS: We aimed to 
      construct and screen out the optimal predictive model based on four GRSs and 
      traditional risk factors. Four GRSs enrolled four SNPs (MTHFR rs1801131, MTHFR 
      rs1801133, MTRR rs1801394, BHMT rs3733890) were presented as follows: (a) simple 
      count genetic risk score (SC-GRS), (b) direct logistic regression genetic risk 
      score (DL-GRS), (c) polygenic genetic risk score (PG-GRS), and (d) explained 
      variance weighted genetic risk score (EV-GRS). We performed a prospective cohort 
      study including 638 HHcy patients. Then we evaluated the associations of four 
      GRSs with folic acid's efficacy and the performance of four GRSs. RESULTS: Four 
      GRSs were independently associated with efficacy of treatment (p < 0.05). When 
      combining GRSs with traditional risk factors, the AUC of the four models were all 
      above 0.900 in the training set (Tradition + SC-GRS: 0.909, Tradition + DL-GRS: 
      0.909, Tradition + PG-GRS: 0.904, Tradition + EV-GRS: 0.910). And EV-GRS got the 
      highest AUC. When evaluating the models in the testing set, we got the same 
      conclusion that EV-GRS was optimal among four GRSs with the highest AUC (0.878) 
      and the highest increase of AUC (0.008). CONCLUSION: A more precise predictive 
      model combing the optimal GRS with traditional risk factors was constructed to 
      predict the efficacy of folic acid therapy to HHcy.
CI  - (c) 2021. The Author(s), under exclusive licence to Springer Nature Limited.
FAU - Chen, Xiaorui
AU  - Chen X
AD  - Department of Epidemiology, School of Public Health, Zhengzhou University, 
      Zhengzhou, Henan, China.
FAU - Huang, Xiaowen
AU  - Huang X
AD  - Department of Epidemiology, School of Public Health, Zhengzhou University, 
      Zhengzhou, Henan, China.
FAU - Zheng, Caifang
AU  - Zheng C
AD  - Department of Epidemiology, School of Public Health, Zhengzhou University, 
      Zhengzhou, Henan, China.
FAU - Wang, Xiliang
AU  - Wang X
AD  - Department of Epidemiology, School of Public Health, Zhengzhou University, 
      Zhengzhou, Henan, China.
FAU - Zhang, Weidong
AU  - Zhang W
AUID- ORCID: 0000-0002-0314-7820
AD  - Department of Epidemiology, School of Public Health, Zhengzhou University, 
      Zhengzhou, Henan, China. imooni@163.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220110
PL  - England
TA  - Eur J Clin Nutr
JT  - European journal of clinical nutrition
JID - 8804070
RN  - 935E97BOY8 (Folic Acid)
SB  - IM
MH  - Folic Acid/therapeutic use
MH  - Genetic Predisposition to Disease
MH  - Humans
MH  - *Hyperhomocysteinemia/drug therapy/genetics
MH  - Polymorphism, Single Nucleotide
MH  - Prospective Studies
MH  - Risk Factors
EDAT- 2022/01/11 06:00
MHDA- 2022/07/14 06:00
CRDT- 2022/01/10 06:23
PHST- 2021/08/05 00:00 [received]
PHST- 2021/11/29 00:00 [accepted]
PHST- 2021/11/22 00:00 [revised]
PHST- 2022/01/11 06:00 [pubmed]
PHST- 2022/07/14 06:00 [medline]
PHST- 2022/01/10 06:23 [entrez]
AID - 10.1038/s41430-021-01055-5 [pii]
AID - 10.1038/s41430-021-01055-5 [doi]
PST - ppublish
SO  - Eur J Clin Nutr. 2022 Jul;76(7):943-949. doi: 10.1038/s41430-021-01055-5. Epub 
      2022 Jan 10.